Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results